Prescription medication · Anticonvulsant (Succinimide)
ethosuximide
Also sold as Zarontin. Ethosuximide is used to control absence seizures, also known as petit mal epilepsy.
Data updated 2026-05-15
- 2,415
- FDA reportsLightly reported
- 3
- InteractionsFew interactions
- $0.23
- Generic price (NADAC)
What the data shows
ethosuximide (Zarontin) is a prescription Anticonvulsant (Succinimide), among the least-reported drugs the FDA tracks (2,415 FDA reports), with 3 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
ethosuximide (Zarontin) is a prescription Anticonvulsant (Succinimide). Ethosuximide is used to control absence seizures, also known as petit mal epilepsy.
Ethosuximide is a medicine that helps control absence seizures. It belongs to a class of drugs called anticonvulsants.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Generic Price
$0.23/unit
Generic Available
Yes (6 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Ethosuximide is used to control absence seizures, also known as petit mal epilepsy.
Common side effects
Loss of appetite, Upset stomach, Nausea
Key warnings
Ethosuximide can cause serious blood problems.
The sections below are summarized in plain English from ethosuximide's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Ethosuximide works by reducing unusual electrical activity in the brain. This helps to prevent absence seizures. The exact way it does this is not completely understood.
Side Effects (from patient reports)
Based on 2,415 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for ethosuximide, by number of reports
- Seizure
Seizure
347 reports
- Somnolence
Somnolence
146 reports
- Generalised Tonic-Clonic Seizure
Generalised Tonic-Clonic Seizure
140 reports
- Petit Mal Epilepsy 117
Petit Mal Epilepsy
117 reports
- Treatment Failure 114
Treatment Failure
114 reports
- Drug Interaction 113
Drug Interaction
113 reports
- Fatigue 109
Fatigue
109 reports
- Epilepsy 105
Epilepsy
105 reports
- Multiple-Drug Resistance 101
Multiple-Drug Resistance
101 reports
- Condition Aggravated 99
Condition Aggravated
99 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for ethosuximide each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where ethosuximide sits
ethosuximide has more FDA adverse-event reports than 15% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is ethosuximide; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 2,415 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.
Total Reports
2,415
Reports Mentioning Death
62
2.6% of reports — not proof of cause
Hospitalization Reports
568
Top Indication
Epilepsy
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 2 | SEIZURE | 347 |
| 4 | SOMNOLENCE | 146 |
| 5 | GENERALISED TONIC-CLONIC SEIZURE | 140 |
| 6 | PETIT MAL EPILEPSY | 117 |
| 7 | TREATMENT FAILURE | 114 |
| 8 | DRUG INTERACTION | 113 |
| 9 | FATIGUE | 109 |
| 10 | EPILEPSY | 105 |
| 11 | MULTIPLE-DRUG RESISTANCE | 101 |
| 12 | CONDITION AGGRAVATED | 99 |
| 13 | VOMITING | 95 |
| 14 | STATUS EPILEPTICUS | 89 |
| 15 | DECREASED APPETITE | 81 |
| 16 | AGGRESSION | 75 |
| 17 | CONVULSION | 74 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Ethosuximide can cause serious blood problems. Tell your doctor right away if you have a fever, sore throat, or unusual bleeding or bruising. Rarely, this medicine can cause severe allergic reactions or liver problems.
Known Drug Interactions
In addition, carbamazepine causes, or would be expected to cause, decreased levels of the following drugs, for which monitoring of concentrations or dosage adjustment may be necessary: acetaminophen, albendazole, alprazolam, aprepitant, buprenorphone, bupropion, citalopram, clonazepam, clozapine, corticosteroids (e.g., prednisolone, dexamethasone), cyclosporine, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, mianserin, midazolam,...
Mechanism: Carbamazepine causes your body to process and remove ethosuximide faster than usual, leading to lower levels of the drug in your system.
Table 1: Drugs That Affect Phenytoin Concentrations Interacting Agent Examples Drugs that may increase phenytoin serum levels Antiepileptic drugs Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole trimethoprim Other Acute alcohol intake, amiodarone,...
Mechanism: Ethosuximide can slow down the breakdown of phenytoin in your body, which may lead to higher levels of phenytoin in your blood.
diazepam, ethosuximide, lamotrigine, phenytoin) by inhibiting their metabolism or protein binding displacement ( 7.2 ) • Patients stabilized on rufinamide should begin valproate therapy at a low dose, and titrate to clinically effective dose ( 7.2 ) • Dosage adjustment of amitriptyline/nortriptyline, propofol, warfarin, and zidovudine may be necessary if used concomitantly with valproate ( 7.2 ) • Topiramate: Hyperammonemia and encephalopathy ( 5.9 , 7.3 ) 7.1 Effects of Co-Administered Drugs on Valproate Clearance Drugs that affect the level of expression of hepatic enzymes, particularly...
Mechanism: Valproate can slow down how your body breaks down ethosuximide or change how it travels in your blood. This can cause the level of ethosuximide in your body to rise.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
Can I take ethosuximide with other seizure medicines?
Will ethosuximide cure my epilepsy?
How long will I need to take ethosuximide?
Can ethosuximide affect my mood?
What should I do if I have side effects?
Can I drink alcohol while taking ethosuximide?
Does ethosuximide interact with other medicines?
Will ethosuximide affect my ability to drive?
How often will I see my doctor while taking ethosuximide?
What do the capsules look like?
What are the common side effects of ethosuximide?
Does ethosuximide interact with other medications?
What drug class is ethosuximide?
What pregnancy or breastfeeding source fields are listed for ethosuximide?
Related Medications in Anticonvulsant (Succinimide)
Other drugs grouped near ethosuximide - same-class peers and common alternatives.
brivaracetam
Briviact
Brivaracetam is a medicine used to treat partial-onset seizures.
Compare with ethosuximide →
cannabidiol
Epidiolex
Epidiolex is a medicine that contains cannabidiol.
Compare with ethosuximide →
carbamazepine
Tegretol
Carbamazepine is a medicine used to control seizures and treat nerve pain.
Compare with ethosuximide →
cenobamate
Xcopri
Xcopri is a medicine used to treat partial-onset seizures in adults.
Compare with ethosuximide →
clobazam
Onfi, Sympazan
Clobazam oral suspension is a medicine used with other medicines to treat seizures caused by Lennox-Gastaut syndrome.
Compare with ethosuximide →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for ethosuximide: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 2,415.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 2.57%.
- cariprazine Δ 0.06 pts · 8,574 reports · Atypical Antipsychotic 2.62%death share
- phenelzine Δ 0.08 pts · 1,551 reports · Monoamine Oxidase Inhibitor (MAOI) 2.64%death share
- bimatoprost Δ 0.14 pts · 28,128 reports · Prostaglandin Analog (Ophthalmic) 2.71%death share
- inclisiran Δ 0.15 pts · 6,989 reports · PCSK9 siRNA 2.72%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on ethosuximide
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for ethosuximide
The FDA label for ethosuximide (sold under brand names such as Zarontin) classifies it as a prescription-only medication in the Anticonvulsant (Succinimide) class. Ethosuximide is used to control absence seizures, also known as petit mal epilepsy. Official labeling lists 18 commonly reported side effects, including Loss of appetite, Upset stomach, Nausea.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 2,415 voluntary reports. The database also lists 3 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated minor severity. NADAC pricing from CMS shows a generic unit cost of $0.23.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: December 23, 2021
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages